Login / Signup

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.

M Angelyn BethelRobert J MentzPeter MerrillJohn B BuseJuliana Chung Ngor ChanShaun G GoodmanNayyar IqbalNeli JakubonieneBrian KatonaYuliya LokhnyginaRenato D LopesAldo P MaggioniPeter OhmanTsvetalina TankovaGeorge L BakrisAdrian F HernandezRury R Holman
Published in: Diabetes care (2019)
EQW had no impact on unadjusted retinopathy or renal outcomes. CV risk was modestly reduced only in those with eGFR ≥60 mL/min/1.73 m2 in analyses unadjusted for multiplicity.
Keyphrases
  • small cell lung cancer
  • epidermal growth factor receptor
  • study protocol
  • clinical trial
  • phase iii
  • tyrosine kinase
  • phase ii
  • randomized controlled trial
  • metabolic syndrome
  • adipose tissue